Rhythm Pharmaceuticals Inc (RYTM)
56.23
-3.54
(-5.92%)
USD |
NASDAQ |
Nov 15, 16:00
56.36
+0.13
(+0.23%)
After-Hours: 20:00
Rhythm Pharmaceuticals Research and Development Expense (TTM): 226.68M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 226.68M |
| June 30, 2024 | 222.32M |
| March 31, 2024 | 225.67M |
| December 31, 2023 | 134.95M |
| September 30, 2023 | 128.61M |
| June 30, 2023 | 116.15M |
| March 31, 2023 | 114.06M |
| December 31, 2022 | 108.63M |
| September 30, 2022 | 116.66M |
| June 30, 2022 | 123.08M |
| March 31, 2022 | 116.73M |
| December 31, 2021 | 104.13M |
| September 30, 2021 | 94.51M |
| June 30, 2021 | 89.96M |
| March 31, 2021 | 87.86M |
| Date | Value |
|---|---|
| December 31, 2020 | 90.45M |
| September 30, 2020 | 93.30M |
| June 30, 2020 | 96.88M |
| March 31, 2020 | 109.19M |
| December 31, 2019 | 109.45M |
| September 30, 2019 | 103.40M |
| June 30, 2019 | 87.54M |
| March 31, 2019 | 60.81M |
| December 31, 2018 | 50.34M |
| September 30, 2018 | 38.23M |
| June 30, 2018 | 33.49M |
| March 31, 2018 | 30.31M |
| December 31, 2017 | 22.89M |
| September 30, 2017 | 21.87M |
| June 30, 2017 | 21.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
87.86M
Minimum
Mar 2021
226.68M
Maximum
Sep 2024
125.46M
Average
111.76M
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 10.53B |
| TG Therapeutics Inc | 87.86M |
| Regeneron Pharmaceuticals Inc | 4.897B |
| Voyager Therapeutics Inc | 113.16M |
| Krystal Biotech Inc | 51.42M |